Form 4: Y-mAbs Therapeutics Director Ashu Tyagi Reports Stock and Option Grants

Director Ashu Tyagi of Y-mAbs Therapeutics reports acquisition of restricted stock units and stock options.

Summary

• On June 11, 2024, Ashu Tyagi, a director of Y-mAbs Therapeutics, reported the acquisition of 3,495 restricted stock units (RSUs) and 14,545 stock options.
• The RSUs were granted under the company's 2018 Equity Incentive Plan and vest on the earlier of the first anniversary of the grant date or the day before the 2025 annual meeting, contingent upon continued service.
• The stock options, also granted under the 2018 plan, vest in equal monthly installments over one year from the grant date and are exercisable immediately upon vesting.
• Following these transactions, Tyagi beneficially owns 5,825 shares of common stock and 14,545 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

This filing is a routine disclosure of equity grants to a company director, common in the biopharmaceutical industry to incentivize management and align their interests with shareholders.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in the biopharmaceutical industry.
• Companies like Amgen, Regeneron, and Biogen routinely grant stock options and RSUs to their directors as part of their compensation packages.
• The vesting schedules and terms of these grants are generally comparable across the industry, with vesting periods typically ranging from one to four years.

Stakeholder Impact

• The equity grants aim to align the director's interests with those of the shareholders, potentially leading to better decision-making and increased company value.
• Employees may view the grants positively as a sign of the company's commitment to incentivizing its leadership.

Key Dates